Vitamin D Levels in Children and Adolescents with Antiepileptic Drug Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study was to evaluate the relationship of 25(OH)D3 levels with anticonvulsantuse and other possible factors in epileptic children and adolescents. Materials and Methods: We studied 143 patients with epilepsy (90 boys, 53 girls; 11.21±4.49 years), who had been treated with anticonvulsants for more than 1 year. Patients who had taken multiple vitamins before the blood test and those who have the limitation of physical activity (wheelchair-bound) were excluded from the study. We evaluated the difference in vitamin D status according to the type and number of anticonvulsants taken and other factors such as gender, age, intelligence and seizure variables. Results: For patients with mental retardation or developmental delay, 25(OH)D3 levels were lower than the levels in patients with normal intelligence quotient levels (p=0.03). 25(OH)D3 levels were lower in patientswho had taken anticonvulsants for more than 2 years as compared to those who had taken them for less than 2 years (p=0.03). Those taking oxcarbazepine had significantly lower vitamin D levels than patients taking valproic acid (p=0.01). However, no effects of number of anticonvulsants taken were detectable. More than two-thirds of the patients were diagnosed with osteopenia or osteoporosisin patients showing either vitamin D insufficiency or deficiency. Conclusion: The possibility of vitamin D deficiency can be considered in pediatric patients takinganticonvulsants if they have mental retardation or developmental delay or if they have been taking anticonvulsants for more than 2 years or taking hepatic enzymeinducing drugs.
Abstract
Purpose: This study was to evaluate the relationship of 25(OH)D3 levels with anticonvulsantuse and other possible factors in epileptic children and adolescents. Materials and Methods: We studied 143 patients with epilepsy (90 boys, 53 girls; 11.21±4.49 years), who had been treated with anticonvulsants for more than 1 year. Patients who had taken multiple vitamins before the blood test and those who have the limitation of physical activity (wheelchair-bound) were excluded from the study. We evaluated the difference in vitamin D status according to the type and number of anticonvulsants taken and other factors such as gender, age, intelligence and seizure variables. Results: For patients with mental retardation or developmental delay, 25(OH)D3 levels were lower than the levels in patients with normal intelligence quotient levels (p=0.03). 25(OH)D3 levels were lower in patientswho had taken anticonvulsants for more than 2 years as compared to those who had taken them for less than 2 years (p=0.03). Those taking oxcarbazepine had significantly lower vitamin D levels than patients taking valproic acid (p=0.01). However, no effects of number of anticonvulsants taken were detectable. More than two-thirds of the patients were diagnosed with osteopenia or osteoporosisin patients showing either vitamin D insufficiency or deficiency. Conclusion: The possibility of vitamin D deficiency can be considered in pediatric patients takinganticonvulsants if they have mental retardation or developmental delay or if they have been taking anticonvulsants for more than 2 years or taking hepatic enzymeinducing drugs.
참고문헌 (19)
- Misra M, "Vitamin D deficiency in children and its management: review of current knowledge and recommendations", Pediatrics, 122, pp.398~417 (2008)
- Rovner AJ, "Hypovitaminosis D among healthy children in the United States: a review of the current evidence", Arch Pediatr Adolesc Med, 162, pp.513~519 (2008)
- Sheth RD, "Bone health in epilepsy", Epilepsia, 43, pp.1453~1454 (2002)
- Pack A, "Bone health in people with epilepsy: is it impaired and what are the risk factors?", Seizure, 17, pp.181~186 (2008)
- Pack AM, "Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications", CNS Drugs, 15, pp.633~642 (2001)
- Bell RD, "Effect of phenytoin on bone and vitamin D metabolism", Ann Neurol, 5, pp.374~378 (1979)
- Mintzer S, "Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine", Epilepsia, 47, pp.510~515 (2006)
- Shellhaas RA, "Vitamin D and bone health among children with epilepsy", Pediatr Neurol, 42, pp.385~393 (2010)
- 권정이, "지적 장애아의 진단과 재활", 대한의사협회지, 52(6), pp.601~610 (2009), 대한의사협회
- Bischoff-Ferrari HA, "Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes", Am J Clin Nutr, 84, pp.18~28 (2006)
- Grant WB, "Benefits and requirements of vitamin D for optimal health: a review", Altern Med Rev, 10, pp.94~111 (2005)
- Kanis JA, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group", Osteoporos Int, 4, pp.368~381 (1994)
- Baker MR, "The decline in vitamin D status with age", Age Ageing, 9, pp.249~252 (1980)
- Kumar J, "Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004", Pediatrics, 124, pp.e362~e370 (2009)
- Nettekoven S, "Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy", Eur J Pediatr, 167, pp.1369~1377 (2008)
- Shellhaas RA, "Vitamin D and bone health among children with epilepsy", Pediatr Neurol, 42, pp.385~393 (2010)
- Cansu A, "Evaluation of bone turnover in epileptic children using oxcarbazepine", Pediatr Neurol, 39, pp.266~271 (2008)
- Guo CY, "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy", Epilepsia, 42, pp.1141~1147 (2001)
- Vanlint S, "Vitamin D and people with intellectual disability", Aust Fam Physician, 37, pp.348~351 (2008)